Published in Cell on March 23, 2007
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol (2008) 6.02
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol (2007) 3.86
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J (2011) 3.06
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Platelets as cellular effectors of inflammation in vascular diseases. Circ Res (2013) 2.62
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Platelets, petechiae, and preservation of the vascular wall. N Engl J Med (2008) 2.25
Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood (2008) 2.20
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol (2012) 2.09
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis (2015) 1.77
BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci (2011) 1.75
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ (2008) 1.73
Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci U S A (2008) 1.73
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood (2013) 1.72
p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood (2009) 1.71
Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev (2011) 1.71
Zebrafish in hematology: sushi or science? Blood (2008) 1.69
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans. PLoS Genet (2012) 1.53
Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood (2014) 1.53
Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med (2009) 1.51
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci U S A (2011) 1.45
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. J Mol Biol (2014) 1.42
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer (2016) 1.42
Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood (2010) 1.41
Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. Arthritis Rheumatol (2016) 1.41
The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ (2015) 1.38
Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer (2013) 1.36
BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 1.33
Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory disease and macrothrombocytopenia. Blood (2007) 1.30
Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission. J Neurophysiol (2007) 1.29
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med (2011) 1.27
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.26
BH3-only proteins in apoptosis at a glance. J Cell Sci (2012) 1.23
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett (2014) 1.23
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer (2011) 1.23
BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci U S A (2010) 1.22
Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. J Thromb Haemost (2013) 1.21
Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc Natl Acad Sci U S A (2009) 1.18
Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One (2011) 1.18
Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ (2013) 1.16
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov (2015) 1.15
The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria. Cell Death Differ (2012) 1.15
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol (2015) 1.14
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov (2014) 1.14
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis (2012) 1.14
Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol (2008) 1.13
Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol (2014) 1.13
Assembly of the Bak apoptotic pore: a critical role for the Bak protein α6 helix in the multimerization of homodimers during apoptosis. J Biol Chem (2013) 1.12
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res (2010) 1.12
Platelet mitochondrial membrane depolarization reflects disease severity in patients with sepsis and correlates with clinical outcome. Crit Care (2014) 1.10
BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem (2011) 1.08
Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2008) 1.08
From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol (2011) 1.08
miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem (2011) 1.08
c-Myb promotes the survival of CD4+CD8+ double-positive thymocytes through upregulation of Bcl-xL. J Immunol (2010) 1.05
Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proc Natl Acad Sci U S A (2013) 1.05
The essential role of evasion from cell death in cancer. Adv Cancer Res (2011) 1.05
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta (2015) 1.05
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat (2011) 1.04
Functions of BCL-X L at the Interface between Cell Death and Metabolism. Int J Cell Biol (2013) 1.02
Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res (2009) 1.01
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med (2014) 1.01
Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death Differ (2010) 1.00
Determinants of platelet count in humans. Haematologica (2011) 1.00
Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis (2011) 0.99
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia (2014) 0.98
Regulation of the autophagic bcl-2/beclin 1 interaction. Cells (2012) 0.98
The genetics of normal platelet reactivity. Blood (2010) 0.98
Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood (2011) 0.97
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A (2015) 0.96
Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance. Oncogene (2014) 0.96
Variability of inducible expression across the hematopoietic system of tetracycline transactivator transgenic mice. PLoS One (2013) 0.96
Kv1.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count. J Physiol (2010) 0.95
Translocation of a Bak C-terminus mutant from cytosol to mitochondria to mediate cytochrome C release: implications for Bak and Bax apoptotic function. PLoS One (2012) 0.95
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death Dis (2012) 0.94
Zebrafish thrombocytes: functions and origins. Adv Hematol (2012) 0.93
Proteasome function is required for platelet production. J Clin Invest (2014) 0.93
Regulatory role of proteasome in determination of platelet life span. J Biol Chem (2013) 0.91
Calpain activator dibucaine induces platelet apoptosis. Int J Mol Sci (2011) 0.91
Apoptosis therapy: driving cancers down the road to ruin. Nat Med (2013) 0.91
Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death Dis (2010) 0.91
Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ (2012) 0.91
Aspirin and clopidogrel alter core temperature and skin blood flow during heat stress. Med Sci Sports Exerc (2013) 0.91
BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One (2014) 0.91
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J (2015) 0.90
Removing the cloak of invisibility: phenotyping the mouse. Dis Model Mech (2008) 0.90
Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation (2014) 0.90
Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med (2014) 0.89
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis (2014) 0.89
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget (2014) 0.89
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett (2014) 0.89
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 8.95
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
ER stress triggers apoptosis by activating BH3-only protein Bim. Cell (2007) 7.50
The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene (2003) 7.41
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol (2007) 5.20
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4.90
Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol (2006) 4.53
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A (2007) 3.41
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet (2011) 3.41
Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature (2002) 3.15
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity (2013) 3.15
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol (2009) 3.14
The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell (2007) 3.13
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med (2007) 3.09
Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat Immunol (2006) 3.09
The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol (2008) 3.07
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
XIAP discriminates between type I and type II FAS-induced apoptosis. Nature (2009) 3.00
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell (2013) 2.75
A homolog of Drosophila grainy head is essential for epidermal integrity in mice. Science (2005) 2.72
BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood (2005) 2.54
A cluster of interferon-γ-inducible p65 GTPases plays a critical role in host defense against Toxoplasma gondii. Immunity (2012) 2.50
Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med (2005) 2.39
PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med (2005) 2.34
HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem (2001) 2.33
SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity (2004) 2.30
How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res (2006) 2.26
Sec15 is an effector for the Rab11 GTPase in mammalian cells. J Biol Chem (2004) 2.24
NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity (2012) 2.14
Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem (2004) 2.12
The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc Natl Acad Sci U S A (2003) 2.12
A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol (2008) 2.04
Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol (2005) 2.01
cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood (2014) 1.97
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest (2006) 1.92
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci U S A (2005) 1.91
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity (2012) 1.89
Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol (2006) 1.85
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A (2008) 1.83
Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci U S A (2004) 1.81
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood (2009) 1.79
betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell (2009) 1.77
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood (2009) 1.74
Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. Immunity (2011) 1.73
Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci U S A (2008) 1.73
Co-ordinate regulation of distinct host cell signalling pathways by multifunctional enteropathogenic Escherichia coli effector molecules. Mol Microbiol (2002) 1.71
Erg is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood (2011) 1.69
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood (2011) 1.69
Mutation discovery in mice by whole exome sequencing. Genome Biol (2011) 1.69
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood (2012) 1.67
Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell (2013) 1.67
Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol (2007) 1.67
SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest (2005) 1.66
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood (2009) 1.63
Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev (2006) 1.61
Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol (2003) 1.60
The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J (2003) 1.59
The combined absence of NF-kappa B1 and c-Rel reveals that overlapping roles for these transcription factors in the B cell lineage are restricted to the activation and function of mature cells. Proc Natl Acad Sci U S A (2002) 1.59
A novel Apaf-1-independent putative caspase-2 activation complex. J Cell Biol (2002) 1.58
Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood (2012) 1.57